A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation factor products. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia A and B.
Annualised bleeding rate (ABR)
Study Arms / Comparison Groups
Haemophilia A patients
Description: Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
May 9, 2017
April 19, 2022
Primary Completion Date
April 19, 2022
Inclusion Criteria: - Have a diagnosis of haemophilia A or B and previously treated with factor Product - Have started prophylactic Elocta/Alprolix treatment prior to enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or Alprolix regardless of participation in the study - Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, Before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations. Exclusion Criteria: - Participation in an investigational medicinal product trial, from four weeks prior to first injection with Elocta or Alprolix to enrollment visit.
N/A - N/A
Accepts Healthy Volunteers
Elena Santagostino, MD, ,
Swedish Orphan Biovitrum
Elena Santagostino, MD, Study Director, Swedish Orphan Biovitrum